A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07598383

Enrollment

120

Registered

2026-05-20

Start date

2026-06-01

Completion date

2027-02-22

Last updated

2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis

Interventions

DRUGVC005 group

VC005 group with Local topical application

DRUGVC005 Placebo group

VC005 Placebo group with Local topical application

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF); 2. The age requirement for signing the ICF is 18 years old or above, with no gender restrictions; 3. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.

Exclusion criteria

1. Patients judged by the investigator to have an unstable course of Atopic Dermatitis (AD) (spontaneous improvement or rapid deterioration) within 2 weeks before baseline; 2. Patients with skin lesions limited to the hands or feet at screening and baseline, with no prior history of involvement in other typical areas (such as the face or flexural folds); 3. Skin damage or abnormalities that may affect the evaluation of the investigational drug administration site (e.g., hyperpigmentation, large-area scars, tattoos, etc. at the affected site); 4. Presence of skin diseases at screening and baseline that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton's syndrome, etc.; 5. Patients with a history of malignant tumors, with the exception of: cervical carcinoma in situ, non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma, or non-metastatic papillary thyroid carcinoma that have been completely resected with no evidence of recurrence for more than 5 years of survival.

Design outcomes

Primary

Measure	Time frame
Changes in EASI（Eczema area and severity index） from baseline	Week 4

Countries

China

Contacts

CONTACTxiaojuan lai

lai_xiaojuan@vcarepharmatech.com+8615358160458

PRINCIPAL_INVESTIGATORLiming Wu

First People's Hospital of Hangzhou

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026